EGFRvIII (also known as EGFRv3), a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy.
In recent years, the role of oncogenic signaling by the epidermal growth factor receptor (EGFR) during gliomagenesis has been intensely studied. In particular, the EGFRvIII mutation has emerged as the central driver of the classic subtype of glioblastomas 1).